During the period from September 2011 to March 2013, a total of 30 TB REACH grants across 24 countries designated funds to procure GeneXpert machines and the Xpert MTB/RIF assay. Of these, a ...

Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...

The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of tuberculosis in decades. David L. Cohn This molecular-based test provides a rapid and sensitive ...

Background The diagnosis of childhood tuberculosis remains a challenge worldwide. The Xpert MTB/RIF test, a rapid mycobacteria tuberculosis diagnostic tool, was recommended for use in children based ...

A study led by Frank Cobelens of the Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands and colleagues reports on the cost-effectiveness of implementing the Xpert MTB/RIF ...

Cepheid has supported TB testing worldwide for over 15 years. Xpert MTB/RIF, released in 2009 in collaboration with the Foundation for Innovative New Diagnostics (FIND), was a first-of-its-kind ...

A potential game-changer in the tuberculosis epidemic was how the tuberculosis community viewed rapid molecular tests for tuberculosis and tuberculosis drug resistance. This was 12 years ago, with the ...

Please provide your email address to receive an email when new articles are posted on . An updated version of the Xpert Mycobacterium tuberculosis and rifampin assay ...

Cepheid ($CPHD) says it gained a key "moderate complexity" CLIA designation for its new combo TB test, helping to position the diagnostic to reach the broadest ...

SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...